InterCure Faces NIS 27 Million Exposure as Key Cannabis Partner Bazelet Enters Restructuring
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Intercure ( (IL:INCR) ).
On December 15, 2025, InterCure Ltd. became aware that Bazelet, a leading producer of cannabis oil and one of its key service providers and customers, had initiated restructuring proceedings in the Israeli District Court, including a request for a temporary stay of proceedings. As a result, approximately NIS 27 million in checks issued by Bazelet to InterCure remain outstanding during the stay, potentially affecting InterCure’s cash flow and operational cooperation with Bazelet. The company said it is closely monitoring the court process, intends to pursue legal actions to protect its rights and interests, and is evaluating collaboration with an additional packaging facility, signaling efforts to mitigate operational and financial exposure tied to Bazelet’s situation.
The most recent analyst rating on (IL:INCR) stock is a Hold with a ILs444.00 price target. To see the full list of analyst forecasts on Intercure stock, see the IL:INCR Stock Forecast page.
More about Intercure
InterCure Ltd., operating as Canndoc, is an Israeli medical cannabis company that provides production, EU-GMP-certified export, and distribution services in the Israeli market, while also supplying raw materials and finished cannabis products to industry partners.
Average Trading Volume: 89,909
Technical Sentiment Signal: Sell
Current Market Cap: ILs240.5M
See more insights into INCR stock on TipRanks’ Stock Analysis page.
